This article was originally published in The Gray Sheet
Files a registration statement with the Securities and Exchange Commission for a proposed public offering of up to 1.3 mil. units consisting of one share of common stock and one series II warrant. Two series II warrants entitle the holder to purchase one share of common stock at 150% of the unit price at any time for a period of two years from the effective date of the offering. The electrotherapeutic device manufacturer also announces that it is extending the term of warrants issued in its 1991 financing, set to expire in June, to the same expiration date as the series II warrants. Staodyn estimates the units will sell at $5 to $6 each, yielding gross proceeds of between $6.5 mil. and $7.8 mil. The firm plans to use $2.6 mil. of the proceeds to repay debt incurred in the acquisition of Technical Medical Devices (TMD) last November. The balance of proceeds will be used for general corporate purposes, which may include "expanding and enhancing" sales and marketing operations, funding R&D efforts, and increasing working capital. The company says it may also use a portion "for potential business or product acquisitions complementary to the company's business." The offering is being underwritten by Cohig & Associates and Paulson Investment Company.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.